A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications.
Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed.
Deal context
The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco's pipeline is built primarily around small molecules, and the company describes its R&D focus as spanning pain management, oncology, respiratory, autoimmune, metabolic, and central nervous system disorders. The pain program being licensed sits within that broader portfolio, which Haisco states includes more than 50 active programs, with over 10 at pivotal clinical stages.
AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson’s, and epilepsy.